Morgan Stanley upgraded Amicus (FOLD) to Overweight from Equal Weight with a $12 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD:
- Amicus Therapeutics Advances Pediatric Fabry Disease Study with Migalastat
- Amicus Therapeutics Advances Pompe Disease Research with New Observational Study
- Amicus Therapeutics’ Migalastat Study: A Potential Game-Changer for Fabry Disease Treatment
- Amicus Therapeutics Expands Access to Migalastat for Fabry Disease Patients
- Amicus Therapeutics Completes Key Study on Pompe Disease Treatment Interactions